ClinicalTrials.gov
ClinicalTrials.gov Menu

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00600236
Recruitment Status : Completed
First Posted : January 24, 2008
Last Update Posted : January 24, 2008
Sponsor:
Collaborator:
Instituto Nacional de Referencia Epidemiológica (INdRE)
Information provided by:
Asociación para Evitar la Ceguera en México

Brief Summary:
One of the first causes of irreversible blindness in mexican population is diabetic retinopathy which is clearly diferent between patients the time of evolution and development of retinopathy and complications. The aim of this study is to explore the inmunogenetic profile and the influence of HLA in this variations of the sickness to predict the severity of diabetic complications.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Type 2 Proliferative Diabetic Retinopathy Procedure: blood sample Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Prevention
Official Title: HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
Study Start Date : September 2004
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
  • Diabetes mellitus type 2 with 10 years of diagnosis and proliferative retinopathy

Exclusion Criteria:

  • Systemic hipertension
  • Cardic disease
  • Lupus
  • Any kind of artritis
  • Allergies
  • Optic Neuritis
  • VKH
  • Cancer
  • Inmunological diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00600236


Locations
Mexico
Asociación para Evitar la Ceguera en México, Hospital "Luis Sanchez Bulnes"
Mexico City, Mexico DF, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Instituto Nacional de Referencia Epidemiológica (INdRE)
Investigators
Principal Investigator: Hugo Quiroz-Mercado, MD Asociación para Evitar la Ceguera en México, Hospital "Luis Sánchez Bulnes"

ClinicalTrials.gov Identifier: NCT00600236     History of Changes
Other Study ID Numbers: APEC-0018
First Posted: January 24, 2008    Key Record Dates
Last Update Posted: January 24, 2008
Last Verified: January 2008

Keywords provided by Asociación para Evitar la Ceguera en México:
Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
Diabetes mellitus type 2 with 10 years of diagnosis and proliferative diabetic retinopathy

Additional relevant MeSH terms:
Diabetes Mellitus
Retinal Diseases
Diabetic Retinopathy
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications